

WHAT IS CLAIMED IS:

5 1. A pharmaceutical composition comprising one or more substances having an activity of inhibiting an effect of nitric oxide *in vivo* and a pharmaceutically acceptable carrier.

10 2. The pharmaceutical composition of Claim 1, wherein the substance having an activity of inhibiting the effect of nitric oxide *in vivo* is a substances having the activity of inhibiting the biosynthesis of nitric oxide *in vivo*.

15 3. The pharmaceutical composition of Claim 2, wherein the substance having the activity of inhibiting the biosynthesis of nitric oxide *in vivo* is a substrate analog of nitrogen monoxide synthase.

20 4. The pharmaceutical composition of Claim 2, wherein the substance having the activity of inhibiting the biosynthesis of nitric oxide *in vivo* is a substance having the activity of inhibiting the catalytic activity of nitric oxide synthase.

25 5. The pharmaceutical composition of Claim 1, wherein the substance having an activity of inhibiting the effect of nitric oxide *in vivo* is a substances having the activity of eliminating nitric oxide *in vivo*.

30 6. The pharmaceutical composition of Claim 3, wherein the substrate analog of nitric oxide synthase is selected from the group consisting of Nw - nitro - L - arginine methyl ester (L-NAME), Nw - monomethyl - L - arginine (L-NMMA), Nw - itro - arginine, Nw - allyl - L - arginine, Nw - cyclopropyl - L - arginine, Nw - amino - L - arginine, Nw - nitro - L - arginine  
35 - p - nitroanilide and Nw, Nw - dimethylarginine.

7. The pharmaceutical composition of Claim 4, wherein the substance having the activity of inhibiting the catalytic activity of nitric oxide synthase is selected from the group consisting of 2 - iminobiotin, L - thiocitruline, L - homothiocitruline, S - methyl-L - thiocitruline, S - ethyl - L - thiocitruline, S - methylisothiourea, S - ethylisochiourea, S - isopropylisothiourea, S, S (1, 3 - phenilenebis (1, 2 - ethanediyl)) bisisothiourea, 2 - amino thiazoline, 2 - aminothiazole, - (3 - (aminomethyl) benzyl) - acetamidine, N (- (4, 5 - dihidrothiazole - 2 - yl) ornithine, N (- iminoethyl - L - ornithine, L - N6 - (1 - iminoehtyl) - lysine, AR - R17477, HMN-1180, (2 - trifluoromethylphenyl) imidazole, 7 - itroindazole, 6 - nitroindazole and indazole.

8. The pharmaceutical composition of Claim 5, wherein the substance having the activity of eliminating nitric oxide *in vivo* is selected from the group consisting of carboxy - 2 - phenyl - 4, 4, 5, 5 - tetramethyl - imidazoline - 1 - oxyl - 3 - oxide and hemoglobin.

9. The pharmaceutical composition of Claim 1 which further comprises one or more agents selected from the group consisting of a histamine H1 receptor antagonist, a local anesthetic and an anti-inflammatory agent.

10. A method of treating noninflammatory pruritus, comprising the step of administrating one or more substances having an activity of inhibiting an effect of nitric oxide *in vivo* to a patient suffering from the pruritus.

11. The method of Claim 10, wherein the substance having an activity of inhibiting the effect of nitric oxide *in vivo* is

a substance having the activity of inhibiting the biosynthesis of nitric oxide *in vivo*.

5

12. The method of Claim 11, wherein the substance having the activity of inhibiting the biosynthesis of nitric oxide *in vivo* is a substrate analog of nitric oxide synthase.

10 13. The method of Claim 11, wherein the substance having the activity of inhibiting the biosynthesis of nitric oxide *in vivo* is a substance having the activity of inhibiting the catalytic activity of nitric oxide synthase.

15 14. The method of Claim 10, wherein the substance having an activity of inhibiting the effect of nitric oxide *in vivo* is a substance having the activity of eliminating nitric oxide *in vivo*.

20 15. The method of Claim 12, wherein the substrate analog of nitric oxide synthase is selected from the group consisting of Nw - nitro - L - arginine methyl ester (L-NAME), Nw - monomethyl - L - arginine (L-NMMA), Nw - itro - arginine, Nw - allyl - L - arginine, Nw - cyclopropyl - L - arginine, Nw - amino - L - arginine, Nw - nitro - L - arginine - p - nitroanilide and  
25 Nw, Nw - dimethylarginine.

16. The method of Claim 13, wherein the substance having the activity of inhibiting the catalytic activity of nitric oxide  
30 synthase is selected from the group consisting of 2 - iminobiotin, L - thiocitruline, L - homothiocitruline, S-methyl-L-thiocitruline, S - ethyl - L - thiocitruline, S - methylisothiourea, S - ethylisochiourea, S - isopropylisothiourea, S, S (1, 3 - phenilenebis (1, 2 -  
35 ethanediyl)) bis - isothiourea, 2-amino thiazoline,

1 45665/VGG/N74

2-aminothiazole, N-(3-(aminomethyl)benzyl)-acetamidine, N(- (4,  
5 - dihydrothiazole - 2 - yl) - ornithine, N( -iminoethyl - L -  
5 ornithine, L - N6 - (1 - iminoethyl)-lysine, AR-R17477, HMN -  
1180, (2 - trifluoromethylphenyl) - imidazole, 7 - nitroindazole,  
6 - nitroindazole and indazole.

17. The method of Claim 14, wherein the substance having  
10 the activity of eliminating nitric oxide *in vivo* is selected from  
the group consisting of carboxy - 2 - phenyl - 4, 4, 5, 5 -  
tetramethyl - imidazoline - 1 - oxyl - 3 - oxide and hemoglobin.

18. A method of treating noninflammatory and inflammatory  
15 pruritus, comprising the step of administering one or more  
substances having an activity of inhibiting an effect of nitric  
oxide *in vivo* and one or more agents selected from the group  
consisting of a histamine H1 receptor antagonist, a local  
anesthetic and an anti-inflammatory agent to a patient suffering  
20 from the pruritus.

25

30

35